A Cost-Effectiveness Analysis of Fingolimod Versus Dimethyl Fumarate As A Second-Line Disease Modifying Treatment In Patients With Highly Active Relapsing-Remitting Multiple Sclerosis

M Raikou; M Kalogeropoulou; G Rombopoulos

doi:10.1016/j.jval.2015.09.2470

A Cost-Effectiveness Analysis of Fingolimod Versus Dimethyl Fumarate As A Second-Line Disease Modifying Treatment In Patients With Highly Active Relapsing-Remitting Multiple Sclerosis

Value in Health ◽

10.1016/j.jval.2015.09.2470 ◽

2015 ◽

Vol 18 (7) ◽

pp. A758 ◽

Cited By ~ 2

Author(s):

M Raikou ◽

M Kalogeropoulou ◽

G Rombopoulos

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Dimethyl Fumarate ◽

Second Line ◽

Highly Active ◽

Effectiveness Analysis ◽

Relapsing Remitting ◽

Disease Modifying ◽

Disease Modifying Treatment ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

Socio-economic status influences access to second-line disease modifying treatment in Relapsing Remitting Multiple Sclerosis patients

PLoS ONE ◽

10.1371/journal.pone.0191646 ◽

2018 ◽

Vol 13 (2) ◽

pp. e0191646 ◽

Cited By ~ 7

Author(s):

Floriane Calocer ◽

Olivier Dejardin ◽

Karine Droulon ◽

Guy Launoy ◽

Gilles Defer

Keyword(s):

Multiple Sclerosis ◽

Economic Status ◽

Second Line ◽

Socio Economic Status ◽

Relapsing Remitting ◽

Disease Modifying ◽

Remitting Multiple Sclerosis ◽

Multiple Sclerosis Patients ◽

Disease Modifying Treatment ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

PND2 TREATMENTS FOR HIGHLY ACTIVE RELAPSING REMITTING MULTIPLE SCLEROSIS: COST-EFFECTIVENESS ANALYSIS IN COLOMBIA

Value in Health Regional Issues ◽

10.1016/j.vhri.2019.08.332 ◽

2019 ◽

Vol 19 ◽

pp. S59

Author(s):

P. Lasalvia ◽

Y. Gil Rojas ◽

F. Hernández ◽

C. Castañeda-Cardona ◽

D. Rosselli

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Cost Effectiveness Analysis ◽

Highly Active ◽

Effectiveness Analysis ◽

Relapsing Remitting ◽

Remitting Multiple Sclerosis ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

PND55 - A COST-EFFECTIVENESS ANALYSIS USING REAL-WORLD DATA FROM THE MSBASE REGISTRY: COMPARING NATALIZUMAB TO FINGOLIMOD IN PATIENTS WITH INADEQUATE RESPONSE TO DISEASE-MODIFYING THERAPIES IN RELAPSING-REMITTING MULTIPLE SCLEROSIS IN ITALY

Value in Health ◽

10.1016/j.jval.2018.09.2021 ◽

2018 ◽

Vol 21 ◽

pp. S338 ◽

Cited By ~ 1

Author(s):

W Herring ◽

IG Gould ◽

G Casamassima ◽

T Dort ◽

Y Zhang ◽

...

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Real World ◽

Inadequate Response ◽

Real World Data ◽

Effectiveness Analysis ◽

Disease Modifying Therapies ◽

Relapsing Remitting ◽

Disease Modifying ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

Peginterferon beta-1a versus other self-injectable disease-modifying therapies in the treatment of relapsing-remitting multiple sclerosis in Scotland: a cost-effectiveness analysis

Journal of Medical Economics ◽

10.1080/13696998.2016.1247712 ◽

2016 ◽

Vol 20 (3) ◽

pp. 228-238 ◽

Cited By ~ 10

Author(s):

Luis Hernandez ◽

Shien Guo ◽

Hector Toro-Diaz ◽

Stuart Carroll ◽

Syed Feisal Syed Farooq

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Cost Effectiveness Analysis ◽

Effectiveness Analysis ◽

Disease Modifying Therapies ◽

Relapsing Remitting ◽

Disease Modifying ◽

Remitting Multiple Sclerosis ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

Effects of Cohort Selection on the Results of Cost-Effectiveness Analysis of Disease-Modifying Drugs for Relapsing-Remitting Multiple Sclerosis

Journal of Managed Care Pharmacy ◽

10.18553/jmcp.2011.17.5.377 ◽

2011 ◽

Vol 17 (5) ◽

pp. 377-381 ◽

Cited By ~ 3

Author(s):

Russell V. Becker III ◽

Carole Dembek

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Cost Effectiveness Analysis ◽

Disease Modifying Drugs ◽

Effectiveness Analysis ◽

Cohort Selection ◽

Relapsing Remitting ◽

Disease Modifying ◽

Remitting Multiple Sclerosis ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

Cost-Effectiveness Analyses of Natalizumab (Tysabri®) Compared with Other Disease-Modifying Therapies for People with Highly Active Relapsing-Remitting Multiple Sclerosis in the UK

PharmacoEconomics ◽

10.2165/00019053-200826070-00008 ◽

2008 ◽

Vol 26 (7) ◽

pp. 617-627 ◽

Cited By ~ 54

Author(s):

Ray Gani ◽

Gavin Giovannoni ◽

David Bates ◽

Belinda Kemball ◽

Steve Hughes ◽

...

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Highly Active ◽

Disease Modifying Therapies ◽

Relapsing Remitting ◽

Disease Modifying ◽

Remitting Multiple Sclerosis ◽

The Uk ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

Cost-Effectiveness Analysis of Delayed-Release Dimethyl-Fumarate In The Treatment of Relapsing-Remitting Multiple Sclerosis In Italy

Value in Health ◽

10.1016/j.jval.2015.09.2598 ◽

2015 ◽

Vol 18 (7) ◽

pp. A697 ◽

Cited By ~ 4

Author(s):

G Furneri ◽

L Santoni ◽

C Marchesi ◽

S Iannazzo ◽

P Cortesi ◽

...

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Dimethyl Fumarate ◽

Cost Effectiveness Analysis ◽

Delayed Release ◽

Effectiveness Analysis ◽

Relapsing Remitting ◽

Remitting Multiple Sclerosis ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

PND24 COST-EFFECTIVENESS ANALYSIS OF DIMETHYL FUMARATE IN THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS IN ITALY

Value in Health ◽

10.1016/j.jval.2019.09.1794 ◽

2019 ◽

Vol 22 ◽

pp. S740-S741

Author(s):

L.G. Mantovani ◽

G. Furneri ◽

P.A. Cortesi ◽

E. Puma ◽

L. Santoni ◽

...

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Dimethyl Fumarate ◽

Cost Effectiveness Analysis ◽

Effectiveness Analysis ◽

Relapsing Remitting ◽

Remitting Multiple Sclerosis ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

Cost-Effectiveness Analysis of Peginterferon Beta-1a Vs. First-Line Injectable Disease-Modifying Therapies For The Treatment of Relapsing-Remitting Multiple Sclerosis In Spain

Value in Health ◽

10.1016/j.jval.2017.08.1948 ◽

2017 ◽

Vol 20 (9) ◽

pp. A723

Author(s):

L Ruiz ◽

H Toro-Diaz ◽

C Cele ◽

L Hernandez ◽

A Harrington

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Cost Effectiveness Analysis ◽

First Line ◽

Effectiveness Analysis ◽

Disease Modifying Therapies ◽

Relapsing Remitting ◽

Disease Modifying ◽

Remitting Multiple Sclerosis ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

PND51 Cladribine Tablets (CT) Versus Other Disease-Modifying Therapies in the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS) - Cost-Effectiveness Analysis.

Value in Health ◽

10.1016/j.jval.2020.08.1376 ◽

2020 ◽

Vol 23 ◽

pp. S632

Author(s):

P. Zięba ◽

D. Pawlik ◽

J. Wieczorek ◽

R. Wojcik ◽

M.P. Kaczor

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Cost Effectiveness Analysis ◽

Effectiveness Analysis ◽

Disease Modifying Therapies ◽

Relapsing Remitting ◽

Disease Modifying ◽

Remitting Multiple Sclerosis ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text